MA-EXAGRID
28.5.2019 17:41:10 CEST | Business Wire | Press release
ExaGrid ® , a leading provider of intelligent hyperconverged storage for backup, today announced that Physicians’ Reciprocal Insurers (PRI) uses ExaGrid disk-based backup systems to significantly increase data protection with secure backups.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190528005580/en/
PRI is a leading provider of professional liability insurance for physicians and medical facilities. As the second largest medical malpractice insurer in New York State and one of the top ten in the U.S., PRI is recognized as one of the most respected names in its field.
PRI replaced its previous system with ExaGrid and Veeam after its IT staff spent too much time troubleshooting backup issues. Al Villani, PRI’s senior system administrator said, “Veritas NetBackup wasn’t set up to send us any kind of alerts if there was an issue, so we had to log in and look through it, which was a lot of manual work. Our calls to Symantec support were sent offshore right away, and by the time they got back to us, we had usually found the solution by searching online. Veritas eventually reacquired NetBackup, but the support never improved.”
ExaGrid solved backup issues PRI had struggled with, including:
- Storage capacity issues
- Backups that exceeded window, slowing company-wide systems during workday
- Time-consuming backup management
- Complicated offsite storage
The security of data storage in the insurance industry has been moving toward stricter regulation, so PRI looked for a solution that would help keep the company ahead of the curve. “The insurance claims we process contain sensitive information, such as birth dates and Social Security numbers—even the tape we used was encrypted, the cases we stored them in were locked, and Iron Mountain had to sign for them—the state regulations are pretty thorough when it comes to security. Many solutions don’t offer encryption or the ability to encrypt at rest like ExaGrid does,” said Villani.
A major issue that PRI faced was that its backups took days and slowed the entire system down, impacting workflow. “Our weekly full backup used to run from Saturday morning at 2:00 a.m. all the way into Tuesday afternoon. Every Monday, users would be calling in and asking why the system was so slow. Now, our weekly full takes just three hours! We thought something was broken the first time we used ExaGrid, so we called our support engineer who confirmed that everything ran correctly. It’s totally incredible! Working with our [ExaGrid] support engineer has been a saving grace. Managing backups had been a nightmare at times, but switching to ExaGrid has been a dream come true. We’re saving about 25-30 hours a week on managing backups. The ExaGrid system doesn’t need a lot of babysitting, and our support engineer is available whenever we need help with any issue.”
As an insurance company, PRI has a complex retention policy for its data. “We keep five weeks of daily backups, eight weeks of weekly backups, a year’s worth of monthly backups onsite, and one yearly onsite with seven yearlies offsite, as well as offsite storage for infinite fiscals and monthly backups,” said Villani. “We were skeptical at first that an ExaGrid system could handle that amount of storage, but the engineers sized everything really well and ExaGrid guaranteed the sizing would work for two years, and that if we needed to add another appliance, they would supply it. Seeing that in writing was pretty impressive!”
Read the complete PRI customer success story to learn more about the company’s experience using ExaGrid.
ExaGrid’s published customer success stories and enterprise stories number over 360, more than all other vendors in the space combined. These stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivalled customer support. Customers consistently state that not only is the product best-in-class, but ‘it just works.’
About ExaGrid
ExaGrid provides intelligent hyperconverged
storage for backup with data deduplication, a unique landing zone, and
scale-out architecture. ExaGrid’s landing zone provides for the fastest
backups, restores, and instant VM recoveries. Its scale-out architecture
includes full appliances in a scale-out system and ensures a
fixed-length backup window as data grows, eliminating expensive forklift
upgrades. Visit us at exagrid.com
or
connect with us on LinkedIn
.
See what our customers have to say about their own ExaGrid experiences
and why they now spend significantly less time on backup.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005580/en/
Contact:
Stacey Foster ExaGrid sfoster@exagrid.com 508-898-2872 x0248
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom